Saw palmetto vs beta-sitosterol for BPH: which has better evidence?
For urinary symptoms of an enlarged prostate, beta-sitosterol has more favourable placebo-controlled results than saw palmetto — but from a handful of short, older trials. The 2023 Cochrane review found saw palmetto alone produces little to no symptom improvement, with mainly high- or moderate-certainty evidence, while a 1999 Cochrane review found beta-sitosterol improved symptom scores and urine flow without shrinking the prostate. Neither has the evidence to replace medical assessment or prescription treatment.
This article answers one question. For what Saw Palmetto is, where it comes from and its other uses, see the Saw Palmetto ingredient guide.
Key findings
- Saw palmetto alone produced little to no symptom improvement in the 2023 Cochrane review, including large independent trials.
- Beta-sitosterol improved IPSS and flow in four short trials (519 men) but did not reduce prostate size.
- The comparison is uneven: newer, larger negative trials versus fewer, older positive ones.
- Guidelines disagree: NICE advises against phytotherapy; the 2023 European guideline gives saw palmetto a weak recommendation.
What human research has studied
Both ingredients have been tested in men with lower urinary tract symptoms from benign prostatic hyperplasia (BPH) — weak stream, frequency, night-time urination and incomplete emptying. The main outcome is the International Prostate Symptom Score (IPSS), a 35-point questionnaire, plus urine flow rate and the volume left in the bladder after urinating.
Saw palmetto
Saw palmetto has far more trials, and the best-designed ones are negative. The 2023 Cochrane review limited its analysis to placebo-controlled comparisons and concluded that saw palmetto alone results in little to no improvement in urinary symptoms, based mainly on high- or moderate-certainty evidence; evidence for saw palmetto combined with other agents was low certainty [1]. Two large independent US trials shaped that picture: the STEP trial, a one-year placebo-controlled study [3], and the CAMUS trial, which tested increasing doses of saw palmetto extract and still found no benefit over placebo [4]. The NCCIH: Saw palmetto summarises the evidence the same way [5].
Beta-sitosterol
Beta-sitosterol has fewer and older trials, but they were more favourable. A Cochrane review of four double-blind trials involving 519 men, lasting 4 to 26 weeks, found that beta-sitosterol improved symptom scores and flow compared with placebo: in the two trials reporting IPSS, the difference was about 4.9 points; peak flow improved by about 3.9 mL per second across four trials; and residual bladder volume fell by about 29 mL. Prostate size did not change, and one trial using a pure beta-sitosterol glucoside preparation showed no flow improvement [2].
Why sources disagree
If beta-sitosterol looks better on paper, why is saw palmetto still the default? Part of the answer is that the evidence is not equivalent in quality. Saw palmetto has recent, large, independent trials with negative results; beta-sitosterol’s positive evidence comes from a small number of short trials reviewed in 1999, and its long-term effectiveness and safety are unknown [2]. A newer positive result on an old evidence base is less certain than a negative result from large modern trials.
Guidelines also differ. According to an American Family Physician Cochrane summary, 2024, the UK’s NICE recommends not offering phytotherapy for BPH symptoms, the 2021 American Urological Association guideline does not include it, and the 2023 European Association of Urology guideline gives a weak recommendation for saw palmetto for men who want to avoid side effects of more effective medicines, while telling them any benefit may be modest [6]. Supporters of specific extracts point to industry-linked analyses of a hexanic saw palmetto extract [7] and to a 2026 review of recent studies that reported more consistent signals with hexanic and beta-sitosterol-enriched preparations, though that review included observational and open-label studies alongside trials [8].
Evidence table
| Study or source | Population | What was tested | Main result | Limitations |
|---|---|---|---|---|
| Cochrane, 2023 [1] | Men with BPH symptoms; placebo-controlled RCTs | Saw palmetto alone or combined | Little to no improvement in urinary symptoms (mainly high/moderate certainty) | Combination evidence low certainty |
| STEP trial (Bent et al., NEJM 2006) [3] | Men with moderate-to-severe BPH symptoms | Saw palmetto extract vs placebo, 1 year | No significant benefit over placebo | One extract |
| CAMUS trial (Barry et al., JAMA 2011) [4] | Men with BPH symptoms | Increasing doses of saw palmetto extract vs placebo | No benefit over placebo, including at higher doses | One extract |
| Cochrane, 1999 [2] | 4 trials; 519 men; 4–26 weeks | Beta-sitosterol preparations vs placebo | IPSS about −4.9 (2 trials); peak flow +3.9 mL/s; residual −29 mL; no size change | Small, short, old; glucoside-only trial negative for flow |
Doses: what each number means
| Amount | What kind of figure it is | Context |
|---|---|---|
| 320 mg/day saw palmetto extract | Study dose | Amount commonly used in major trials; CAMUS escalated above it without benefit |
| Beta-sitosterol amounts varied | Study dose | Different preparations across four trials; no single effective dose defined |
| No RDA or upper limit | Regulatory | Neither ingredient is a nutrient |
| Saw palmetto “berry powder” amounts | Commercial dose | Not equivalent to standardised extracts used in trials |
A dose used in a study describes what researchers gave participants. It is not a personal recommendation, and it does not mean a lower or higher amount is safe or effective for you.
Neither ingredient is a nutrient, so there are no recommended intakes or upper limits. Beta-sitosterol trials used different preparations and amounts, and the Cochrane review did not define a single effective dose [2]; a label amount cannot be matched confidently to “the” study dose.
Form and extract differences
- Saw palmetto extract type: hexanic, ethanolic and supercritical CO₂ extracts differ in composition. Positive claims are often made for specific branded hexanic extracts; the independent negative trials used their own standardised extracts.
- Saw palmetto berry powder: whole-berry powder is not equivalent to a standardised lipidosterolic extract.
- Beta-sitosterol preparations: the Cochrane review distinguished non-glucosidic beta-sitosterol mixtures, which improved flow, from a pure beta-sitosterol glucoside preparation, which did not [2]. “Plant sterols” on a label may be a different mix again.
Safety
- Both ingredients were generally well tolerated in trials; withdrawal rates in the beta-sitosterol review were similar to placebo (7.8% vs 8.0%) [2].
- Saw palmetto commonly causes mild digestive upset and headache, according to NCCIH [5].
- The larger risk is delay: urinary symptoms can come from infection, bladder problems or prostate cancer, and supplements do not rule these out.
Interactions
- BPH medicines: adding supplements to tamsulosin, finasteride or dutasteride complicates judging what is working; tell your prescriber.
- Anticoagulants and surgery: saw palmetto is often flagged for possible effects on bleeding; mention it before procedures.
- Hormonal treatments: saw palmetto is marketed for effects on androgen pathways, so people using hormonal therapies should ask a clinician.
Populations requiring caution
- Men whose symptoms have not been assessed, including PSA and examination where appropriate.
- Men with blood in the urine, fever, pain, inability to urinate or bone pain — these need prompt medical care.
- Men taking prescription BPH or hormonal medicines.
- Women and children: these ingredients are not studied for these uses.
Limitations of the research
- Beta-sitosterol evidence is small, short and old, with unknown long-term effects.
- Saw palmetto trials used different extracts, and debate continues about whether specific extracts behave differently.
- Industry funding is common among positive analyses of branded extracts.
- Few trials compare saw palmetto and beta-sitosterol directly.
- Most combination prostate supplements have not been tested as finished products.
Practical label reading
- For saw palmetto, look for an extract (not berry powder) with a stated amount and standardisation.
- For beta-sitosterol, look for a milligram amount of beta-sitosterol specifically, not just “plant sterols” or a blend total.
- In combination products, check whether either ingredient is hidden inside a proprietary blend.
- Be sceptical of claims to shrink the prostate; neither ingredient reduced prostate size in the reviews above.
See our prostate supplements comparison and reviews of TitanFlow and ProstaPeak. Browse the prostate category, the beta-sitosterol guide, or read does saw palmetto work for the prostate.
Frequently asked questions
Is beta-sitosterol better than saw palmetto?
On published placebo-controlled evidence, beta-sitosterol looks more favourable, but its trials are few, short and old, whereas saw palmetto’s negative results come from larger, more recent trials. Neither is established as equivalent to prescription BPH treatment.
Does saw palmetto work at a higher dose?
The CAMUS trial tested increasing doses and found no benefit over placebo.
Can either ingredient shrink the prostate?
No. The beta-sitosterol review found no change in prostate size, and saw palmetto has not been shown to shrink the prostate.
What dose of beta-sitosterol was studied?
Trials used different preparations and amounts, and the Cochrane review did not define a single effective dose.
Why do some urology guidelines still mention saw palmetto?
The 2023 European guideline gives it a weak recommendation for men wanting to avoid drug side effects, with a warning that benefit may be modest; UK and US guidance do not recommend phytotherapy.
Should I get checked before taking a prostate supplement?
Yes. Urinary symptoms have several causes, and a clinician can assess for infection, bladder problems and prostate cancer.
References
- Franco JVA, Trivisonno L, Sgarbossa NJ, et al. Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Cochrane Database Syst Rev. 2023;6:CD001423. PMID 37345871
- Wilt T, Ishani A, MacDonald R, Stark G, Mulrow C, Lau J. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev. 1999. PMID 10796740
- Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med. 2006;354(6):557–566.
- Barry MJ, Meleth S, Lee JY, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA. 2011;306:1344–1351.
- NCCIH: Saw palmetto.
- American Family Physician Cochrane summary, 2024.
- Efficacy and safety of a hexanic extract of Serenoa repens (Permixon®) for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: systematic review and meta-analysis of randomised controlled trials and observational studies. BJU Int. 2018;122:1049–1065.
- Drugs in Context systematic review, 2026.